SANTA CLARITA, Calif., July 22, 2024 /PRNewswire/ -- StimAire, a paradigm-shifting injectable neuromodulation company developing medical devices for obstructive sleep apnea (OSA), is pleased to announce the appointment of Arthur Rascon as Chief Operating Officer (COO), effective July 22, 2024.

加利福尼亚州圣克拉丽塔，2024年7月22日/PRNewswire/--StimAire，一家开发阻塞性睡眠呼吸暂停（OSA）医疗设备的范式转换注射神经调节公司，很高兴宣布任命Arthur Rascon为首席运营官（COO），自2024年7月22日起生效。

Mr. Rascon brings over two decades of experience in operational leadership and a proven track record of driving innovation and commercialization in the medical device industry. Prior to joining StimAire, Arthur Rascon served as the Chief Executive Officer at Valencia Technologies Corporation, where he led the company's neuromodulation therapies..

Rascon先生在运营领导方面拥有20多年的经验，在推动医疗器械行业的创新和商业化方面有着良好的业绩记录。在加入StimAire之前，Arthur Rascon曾担任巴伦西亚科技公司（Valencia Technologies Corporation）的首席执行官，领导该公司的神经调节疗法。。

Before Valencia Technologies, Arthur was Senior Director of Manufacturing Engineering at Medtronic Diabetes, where he played a crucial role in enhancing manufacturing processes and ensuring product quality.

在瓦伦西亚科技之前，亚瑟是美敦力糖尿病公司制造工程的高级主管，他在改进制造工艺和确保产品质量方面发挥了至关重要的作用。

At Advanced Bionics, Arthur served as Vice President of Manufacturing and Quality Engineering, and Senior Director of Product Engineering, where he was instrumental in product development and operational management.

在Advanced Bionics，Arthur担任制造和质量工程副总裁以及产品工程高级总监，在产品开发和运营管理方面发挥了重要作用。

'We are thrilled to welcome Arthur Rascon to the full-time leadership team,' said Tarek Makansi PhD, President and Chief Technology Officer of StimAire. 'Arthur will move our company and product forward from a demonstrated technology to a certified medical device offering with the goal of improving the lives of those affected by obstructive sleep apnea.'.

StimAire总裁兼首席技术官塔里克·马坎西博士（TarekMakansi）说，我们很高兴欢迎亚瑟·拉斯康（ArthurRascon）加入全职领导团队Arthur将把我们的公司和产品从一种经过验证的技术发展为一种经过认证的医疗设备，目的是改善阻塞性睡眠呼吸暂停患者的生活。”。

Arthur Rascon said 'I am deeply impressed with StimAire's ultra-tiny injectable neuromodulation device, which already has human data supporting efficacy and safety. The path to a successful product is very clear to me, and the recent Breakthrough Device Designation from the FDA will accelerate our progress'..

亚瑟·拉斯康（ArthurRascon）说，“StimAire的超微型可注射神经调节装置给我留下了深刻的印象，该装置已经拥有支持疗效和安全性的人体数据。成功产品的道路对我来说非常清楚，FDA最近的突破性设备设计将加速我们的进步'。。

StimAire recently completed its first-in-human study of its groundbreaking injectable stimulator for OSA, marking a significant milestone in the company's journey to provide innovative solutions for sleep disorders.

StimAire最近完成了其开创性的OSA注射刺激器的首次人体研究，标志着该公司为睡眠障碍提供创新解决方案的历程中的一个重要里程碑。

StimAire is a portfolio company of University Associates Venture Capital (UAVC). For more information about StimAire and UAVC, please visit www.stimaire.com or www.uaventurecap.com.

StimAire是大学联合风险投资（UAVC）的投资组合公司。有关StimAire和UAVC的更多信息，请访问www.StimAire.com或www.uaventurecap.com。

SOURCE StimAire Inc

来源：Stimaire公司